improving outcomes in flt3-mutated aml patients
Published 5 years ago • 299 plays • Length 4:32Download video MP4
Download video MP3
Similar videos
-
2:26
improving outcomes for flt3-mutated r/r aml
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
1:32
novel treatment combinations for flt3-mutated aml
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
3:14
flt3 mutations for targeted therapy in aml
-
2:27
gilteritinib maintenance after allogeneic transplantation in flt3-mutated aml
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
43:10
venetoclax plus gilteritinib for flt3-mutated relapsed/refractory acute myeloid leukemia
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
1:24
mechanisms of resistance to flt3 inhibitors in aml and strategies to overcome this
-
6:47
the 2021 treatment algorithm for flt3-mutated aml
-
1:20
flt3 inhibitors as mrd-guided salvage treatment for molecular failure in flt3-mutated aml
-
2:42
the use of targeted therapy to prevent relapse post-transplant
-
1:04
continuous treatment with flt3 inhibitors for patients with flt3-mutated aml undergoing allosct
-
1:58
unanswered questions that remain in flt3-mutated aml
-
2:38
flt3 inhibitors: revolutionizing the management of aml
-
1:52
the management of r/r flt3-mutated aml
-
1:33
the importance of measurable residual flt3-itd before allosct for aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo